Twitxy Saved

John Craig, MD

@JohnCraigNose

Rhinologist at Henry Ford Health; I might like noses, sinuses, and the skull base
Detroit, MI youtube.com/channel/UCC5SX… Joined March 2017
289 Following 1.5K Followers 1.5K Posts

Latest posts 5

John Craig, MD @JohnCraigNose
Whoa. But check out the ipratropium paper. Actually find it really helpful using ipratropium to help guide whether certain clear thin rhinorrhea is or is not CSF. Was a cool 5 year study 😎
Piyush Verified account @drpiyushENT 5d
On it, thank you. Forgive my methods. Lord knows, i am overwhelmed right now.

CSF Rhinorrhea — Questions Explicitly Asked in the Lecture

The Art and Science of Diagnosing Nasal CSF Leaks | Questions arranged chronologically with video timestamps.

Anatomy and etiology (00:40–05:50)

1️⃣ What are the tissue layers from sinus mucosa to brain parenchyma? (00:40)
→ Mucosa → periosteum → bone → dura → arachnoid → subarachnoid space → pia → brain.

2️⃣ What comes after the dura? (01:00)
→ Arachnoid mater, followed by subarachnoid CSF space.

3️⃣ Damage to which layers causes CSF rhinorrhea? (01:15)
→ A patent defect extending from the subarachnoid space through the meningeal and sinonasal barriers.

4️⃣ What are the potential sites of nasal CSF leakage? (01:56)
→ Cribriform plate, lateral lamella, fovea ethmoidalis, planum, sella, clivus, sphenoid lateral recess, posterior frontal table, tegmen and petrous apex.

5️⃣ What are the complications of CSF leaks? (03:46)
→ Meningitis, brain abscess, pneumocephalus and tension pneumocephalus.

6️⃣ How would you classify CSF leak etiologies? (04:51)
→ Traumatic (accidental/iatrogenic), spontaneous, tumor-related and congenital.

7️⃣ How would you define idiopathic intracranial hypertension? (05:32)
→ Elevated intracranial pressure without an identified secondary cause, meeting appropriate diagnostic criteria.

8️⃣ Do most patients with IIH develop CSF leaks? (05:37)
→ No.

9️⃣ What is the incidence of CSF leaks among patients with IIH? (05:45)
→ Lecturer did not provide a reliable incidence.

IIH and MRI (07:29–11:33)

🔟 What is the difference between photopsia and transient visual obscurations? (07:29)
→ Lecturer explicitly said he was uncertain; no definitive answer given.

1️⃣1️⃣ What is the diaphragma sellae? (08:23)
→ Dural roof of the pituitary fossa, perforated by the pituitary stalk.

1️⃣2️⃣ What is an empty sella? (08:30)
→ CSF expansion within the sella with flattening of the pituitary gland.

1️⃣3️⃣ How does the arachnoid produce an empty sella? (09:14)
→ Proposed herniation through the diaphragma sellae, allowing CSF extension into the sella. Lecturer acknowledged mechanistic uncertainty.

1️⃣4️⃣ What other MRI findings are associated with IIH? (10:36)
→ Empty sella, perioptic CSF-space distension and transverse sinus stenosis.

Clinical diagnosis (11:38–16:05)

1️⃣5️⃣ How do you work up a patient presenting with suspected CSF rhinorrhea? (11:41)
→ Detailed history → examination → biochemical confirmation → anatomical localization.

1️⃣6️⃣ Which additional symptoms raise suspicion for CSF rhinorrhea? (11:48)
→ Unilateral watery positional drainage, straining-related leakage, preceding trauma/surgery, meningitis or IIH symptoms.

1️⃣7️⃣ What is the overarching diagnostic concept? (11:55)
→ Confirm, then localize.

1️⃣8️⃣ What proportion of patients with unilateral clear rhinorrhea actually have CSF leaks? (14:28)
→ Approximately 30% in the lecturer's specialist-practice cohort; nearly 50% had nonallergic rhinitis.

1️⃣9️⃣ How good is the halo test? (15:35)
→ Unreliable and nonspecific; lecturer loosely estimated sensitivity/specificity around 50%.
β2-transferrin and β-trace protein (16:06–24:03)

2️⃣0️⃣ What is β2-transferrin? (16:06)
→ A desialylated transferrin isoform found in CSF, perilymph and aqueous humor.

2️⃣1️⃣ What is the relevance of neuraminic acid? (16:14)
→ Loss of sialic acid residues changes transferrin's charge and electrophoretic migration.

2️⃣2️⃣ What type of laboratory test detects β2-transferrin? (18:41)
→ Qualitative immunofixation gel electrophoresis.

2️⃣3️⃣ Why does the qualitative nature of β2-transferrin testing matter? (18:56)
→ Band intensity and interpretation depend on concentration and laboratory expertise; false interpretation is possible.

2️⃣4️⃣ How long is β2-transferrin stable after collection? (20:30)
→ Detectable for 7 days in an earlier small study and up to 14 days in the lecturer's study under tested conditions.

2️⃣5️⃣ Have you heard of β-trace protein? What is it? (23:00)
→ Lipocalin-type prostaglandin D synthase, abundant in CSF; rapid testing is possible with very small samples.

Radionuclide cisternography (24:04–28:31)

2️⃣6️⃣ What is radionuclide cisternography? (24:08)
→ Intrathecal administration of a radiotracer, followed by imaging and/or nasal pledget radioactivity measurement to detect CSF escape.

2️⃣7️⃣ When might you use radionuclide cisternography? (25:38)
→ Selected intermittent leaks or cases where fluid collection is impossible, although the lecturer questions its diagnostic value.

CT and MRI localization (28:32–32:24)

2️⃣8️⃣ What is the first imaging investigation for a confirmed CSF leak? (28:38)
→ High-resolution CT with ≤1 mm sections.

2️⃣9️⃣ How can you establish whether a CT-demonstrated bony defect is actually leaking? (29:29)
→ Demonstrate CSF communication using appropriate cisternography or operative localization.

3️⃣0️⃣ What is injected for CT cisternography? (29:37)
→ Intrathecal iodinated contrast.

3️⃣1️⃣ What are the disadvantages of CT cisternography? (31:03)
→ Invasive lumbar puncture, contrast administration, logistical complexity and false negatives when the leak is inactive.

3️⃣2️⃣ What is MR cisternography? (31:35)
→ Heavily T2-weighted MRI used to visualize CSF-containing pathways, meningoceles and potential fistulas without intrathecal injection in the non-contrast technique.

Intrathecal fluorescein and exploration (32:25–37:25)

3️⃣3️⃣ If β2-transferrin collection is inadequate and cisternography is equivocal, what else can you do? (32:25)
→ Consider surgical exploration with intrathecal fluorescein when clinical and anatomical evidence justifies it.

3️⃣4️⃣ How is intrathecal fluorescein used? (32:35)
→ Specialist-controlled intrathecal administration followed by endoscopic visualization of fluorescent CSF leakage.

3️⃣5️⃣ What are its important complications? (33:33)
→ Seizures and other neurological toxicity, including historically reported paralysis.

3️⃣6️⃣ What dosage of intrathecal fluorescein was described? (33:54)
→ Traditional regimen: 0.1 mL of 10% fluorescein (10 mg), diluted in approximately 10 mL CSF and slowly administered over 10 minutes.

3️⃣7️⃣ How many seizures occurred in the lecturer's institution over 7.5 years? (34:23)
→ Zero reported.

3️⃣8️⃣ Why administer fluorescein slowly over 10 minutes? (34:35)
→ The lecturer questioned the evidence supporting that exact duration. His institutional experience does not establish that rapid administration is safe.

3️⃣9️⃣ What do you do if β2-transferrin is positive but no fluorescein is visible intraoperatively? (34:40)
→ Reassess the diagnosis, verify administration, review imaging and consider intermittent leakage before deciding further exploration.

4️⃣0️⃣ Should you stop at diagnostic endoscopy when fluorescein is negative, or continue surgery? (34:58)
→ Lecturer favors proceeding with appropriately planned exploration when preoperative suspicion is sufficiently high.

4️⃣1️⃣ What do you do when fluorescein remains negative despite high clinical suspicion? (35:41–36:33)
→ Re-review CT/MRI, consider false results, perform targeted exposure and consider maneuvers to provoke leakage.

4️⃣2️⃣ Should you wait longer, reposition the patient or perform Valsalva? (36:52)
→ Lecturer describes using additional time, positioning and Valsalva; their effectiveness requires better study.

4️⃣3️⃣ Why do we sometimes fail to see fluorescein in proven leaks? (37:10)
→ Uncertain; possible intermittent flow, low-volume leakage or timing factors. Lecturer states further investigation is needed.
Improving the diagnostic algorithm (37:37–42:13)

4️⃣4️⃣ How could the diagnostic workup of CSF rhinorrhea be improved? (37:37)
→ Better clinical risk stratification to avoid unnecessary invasive investigations in low-probability patients.

4️⃣5️⃣ Should low-suspicion patients undergo further testing? (39:10)
→ Unresolved gray area; lecturer suggests considering alternative rhinitis treatment and individualized investigation.

4️⃣6️⃣ What is a potential simple solution for improving screening? (39:28)
→ Intranasal ipratropium bromide.

4️⃣7️⃣ What if ipratropium were used to screen patients presenting with unilateral watery rhinorrhea? (39:57)
→ The lecturer investigated whether symptomatic response predicts absence of a CSF fistula.

4️⃣8️⃣ Can ipratropium nasal spray be used to screen for CSF leaks? (41:20)
→ Investigational. In the lecturer's study, none of the confirmed CSF-leak patients responded, but this was not established as a validated exclusion test.
View quoted post on X